Murty Pharmaceuticals, Inc.
Lexington, KY
- UEI
- DNJBTJ3XBQM6
- CAGE
- 3BJ06
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 518 Codell Dr, Lexington, KY 40509, USA
- Website
- mpirx.com
- Founded
- 1995
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| FY24. To 5 - drug product stability studies. POP 9/13/24-9/12/25. | National Institute on Drug Abuse | $90,784 | |
| FY23. Drug product stability studies. Period of performance: september 13, 2023 - september 12, 2024 | National Institute on Drug Abuse | $90,784 | |
| Manufacture of morphine sulfate pellets task order 03, FY23 | National Institute on Drug Abuse | $245,582 | |
| FY22. Drug product stability studies. POP 9/23/22 - 9/22/23. | National Institute on Drug Abuse | $88,415 | |
| FY26. To 7 - drug product stability studies. POP 9/13/26-9/12/27. | Office of Logisitics and Acquisition Operations | $92,724 |
About Murty Pharmaceuticals, Inc.
Murty Pharmaceuticals, Inc. is a minority-owned, small disadvantaged business located in Lexington, Kentucky, specializing in pharmaceutical research, development, and manufacturing. Registered in SAM.gov since 2002, the company is structured as a for-profit, Subchapter S Corporation with a focus on developing pharmaceutical products for substance use disorder treatments. As a manufacturer of goods with a specific emphasis on pharmaceutical research, Murty Pharmaceuticals has established itself as a key contractor for federal agencies, particularly in the realm of pharmaceutical development for addiction and substance abuse research.
The company has consistently secured federal contract awards from the National Institute on Drug Abuse (NIDA), primarily performing specialized pharmaceutical research and manufacturing services. These contracts have included critical scientific work such as drug product stability studies, manufacture of specialized pharmaceutical compounds like morphine sulfate pellets, and production of controlled substances for research purposes. Specifically, Murty Pharmaceuticals has completed contracts involving the manufacture of Good Manufacturing Practice (GMP) methamphetamine hydrochloride for intravenous injection and various drug stability studies. Their contract awards, ranging from $88,415 to $245,582, have been consistently awarded without specific small business set-aside designations, indicating the company's competitive capabilities in pharmaceutical research and manufacturing.
Murty Pharmaceuticals holds a significant $7 million single-award indefinite delivery contract with NIDA, effective through September 2026, which serves as the primary vehicle for their federal contract work. This contract enables the company to provide comprehensive pharmaceutical development services, including formulation development, clinical trial materials production, analytical testing, and stability studies for drug products related to substance abuse treatment. The contract's broad scope allows Murty Pharmaceuticals to support NIDA's medications development program for addiction treatment, performing specialized pharmaceutical preparation work that requires precision, scientific expertise, and compliance with FDA regulations. Task orders under this contract have consistently focused on developing pharmaceutical products for treating substance use disorders, highlighting the company's specialized role in supporting critical medical research through sophisticated pharmaceutical manufacturing and development services.
Contract vehicles
SBA capabilities narrative
Murty Pharmaceuticals, Inc. provides drug formulation development, analytical lab testing, and manufacturing scale up services.
Quick answers
What is Murty Pharmaceuticals, Inc.'s UEI?
Murty Pharmaceuticals, Inc.'s Unique Entity ID (UEI) in SAM.gov is DNJBTJ3XBQM6.
What is Murty Pharmaceuticals, Inc.'s CAGE code?
Murty Pharmaceuticals, Inc.'s CAGE code is 3BJ06.
What is Murty Pharmaceuticals, Inc.'s primary NAICS code?
Murty Pharmaceuticals, Inc.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Murty Pharmaceuticals, Inc. located?
Murty Pharmaceuticals, Inc.'s physical address in SAM.gov is 518 Codell Dr, Lexington, KY 40509, USA.
Is Murty Pharmaceuticals, Inc. registered in SAM.gov?
Yes. Murty Pharmaceuticals, Inc.'s SAM.gov registration is active through February 23, 2027.
Which contract vehicles does Murty Pharmaceuticals, Inc. hold?
Murty Pharmaceuticals, Inc. holds a place on 2 federal contract vehicles, including Drug Formulation and Manufacturing Contracts 2019 and NCATS Drug Product Development Studies 2017-2022.
What is Murty Pharmaceuticals, Inc.'s most recent federal award?
Murty Pharmaceuticals, Inc.'s most recent federal contract award is FY24. To 5 - drug product stability studies. POP 9/13/24-9/12/25 (75N95024F00001), from National Institute on Drug Abuse, on September 13, 2024.
On GovTribe
See Murty Pharmaceuticals, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors